NHMRC Review Supports Puberty Blockers as an Option for Eligible Australian Youth
16 Nov 2026
Puberty blockers should remain an option for some young Australians experiencing gender incongruence, according to new interim advice from the National Health and Medical Research Council (NHMRC).
The review recommends that medicines known as gonadotropin-releasing hormone (GnRH) agonists may be offered to eligible young people under 18 who have started puberty and have been assessed as suitable for treatment.
The decision should involve the young person, their parents or carers, and their healthcare team. Each case should be assessed individually before treatment is considered.
The NHMRC also explains that puberty blockers are one possible part of a broader approach to care. Young people do not need to wait until they experience distress before receiving appropriate healthcare support.
The review stresses that treatment decisions should not follow a single approach for everyone. Instead, healthcare professionals should consider each young person's circumstances, personal goals, values and health needs.
For young people who are still exploring their gender identity, puberty suppression may provide additional time to discuss treatment options and better understand their needs.
The NHMRC also warns that delaying care simply to see how puberty progresses may not reduce distress and could affect a young person's physical health, mental wellbeing and daily life.
NHMRC Acting Chief Executive Prue Torrance said the national guidance aims to help healthcare professionals make careful, individualised decisions.
She said young people and their families should have access to clear medical information and be able to discuss their options with healthcare professionals using the best available evidence.
Torrance also highlighted the importance of shared decision-making, involving the young person, their parents or carers, and their clinicians.
RACGP President Dr Michael Wright said the college is reviewing the NHMRC's interim advice.
He noted that the recommendations follow a detailed review of evidence covering outcomes important to patients, families and healthcare professionals. He also confirmed that the RACGP would consult its members and relevant specialist interest groups before deciding on its next steps.
The review follows earlier restrictions on gender-affirming healthcare for young people in Australia. Almost two years ago, the Queensland Government paused gender-affirming hormone therapy for people under 18 in the state.
In December 2025, the Northern Territory Government also announced it would stop funding puberty blockers and gender-affirming hormone treatments for children.
Federal Health and Ageing Minister Mark Butler, who requested the development of the national guidelines, said public gender services for young people are managed by state and territory governments.
However, he stressed that governments have a responsibility to ensure young Australians receive appropriate medical advice and care.
Butler said treatment decisions should involve clear information for young people and their families, a thorough health assessment, input from a multidisciplinary healthcare team and regular monitoring.
Public consultation on the NHMRC's interim advice is now open. The full national clinical guidelines are expected to be released in 2028.
NHMRC Review Supports Puberty Blockers as an Option for Eligible Australian Youth
Source: National Health and Medical Research Council (NHMRC) – Advice on Puberty Suppressants